# Effects of Zoledronic Acid and Raloxifene on Bone Turnover Markers in Postmenopausal Women With Low Bone Mineral Density

> **NCT00431444** · PHASE4 · COMPLETED · sponsor: **Novartis** · enrollment: 110 (actual)

## Conditions studied

- Osteoporosis

## Interventions

- **DRUG:** Raloxifene
- **DRUG:** Zoledronic acid
- **DRUG:** Placebo oral pills
- **DRUG:** Placebo intravenous (i.v.) infusion

## Key facts

- **NCT ID:** NCT00431444
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2008-07
- **Final completion:** 2008-07
- **Target enrollment:** 110 (ACTUAL)
- **Last updated:** 2011-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00431444

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00431444, "Effects of Zoledronic Acid and Raloxifene on Bone Turnover Markers in Postmenopausal Women With Low Bone Mineral Density". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00431444. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*